For emergency parenteral administration in dogs, cats, equids, and food-producing species, epinephrine hydrochloride is formulated as a sterile solution at a nominal concentration of 1 mg/mL expressed as epinephrine base. The aqueous vehicle consists of water for injection, sodium chloride at 9.0 mg/mL, and sodium metabisulfite as antioxidant at a typical concentration of 0.1% w/v. The solution is adjusted with hydrochloric acid or sodium hydroxide to a pH range of 2.2–5.0, with production-scale batches usually targeted to 3.0–3.5. The low pH maintains the catechol moiety in its protonated form, which retards autoxidation, but pH values below 2.2 increase injection-site pain and can precipitate local tissue reactions in small animals. A nitrogen or argon headspace is applied after filling into amber Type I glass ampoules or vials because epinephrine is sensitive to oxygen and light. The product is not routinely autoclaved at 121°C for 15 min unless specific stability data demonstrate absence of adrenochrome discolouration. Aseptic processing through a 0.22 µm polyvinylidene fluoride filter under EU GMP Annex 1 conditions is the preferred route. Finished product is tested against USP <71> for sterility, USP <788> for particulate matter, and USP <791> for pH.

In the United States, veterinary epinephrine injection is listed in 21 CFR 522.810; where extralabel use occurs in food-producing species, the withdrawal and residue rules of 21 CFR 530 apply. Some monographs permit a label claim of 1:1000 epinephrine injection, which corresponds to 1 mg/mL. On production lines, batch-to-batch variance in sodium metabisulfite content occurs because this antioxidant is reactive in aqueous systems when nitrogen sparging is insufficient. Inline dissolved oxygen probes positioned downstream of the filling needles are used to verify inert conditions. Prolonged exposure to stainless steel surfaces can introduce trace iron and accelerate catechol degradation; contact surfaces are therefore typically fabricated from 316L electropolished and passivated steel. The final solution must remain colourless; any pink-to-brown discolouration indicates adrenochrome formation and is a rejection criterion.

What Changes When Epinephrine is Added to Lidocaine Regional Blocks?

Commercial veterinary dental and surgical packs commonly source lidocaine hydrochloride 2% w/v with epinephrine 5 µg/mL or 10 µg/mL from human-approved cartridge presentations. The epinephrine concentration is expressed as base; a 1:200,000 strength corresponds to 5 µg/mL, and 1:100,000 corresponds to 10 µg/mL. In these co-formulations, epinephrine functions as a local vasoconstrictor, slowing systemic absorption of lidocaine from the infiltration site and prolonging nerve block duration in species where local blood flow is high. The addition of epinephrine also permits a reduction in peak plasma lidocaine concentration, but published comparative data for food-producing species are limited. The pH of the combined solution is deliberately kept in the acidic range, usually below 5.0, to stabilize epinephrine; however, this acidity contributes to injection-site irritation. Buffering with sodium bicarbonate 8.4% w/v immediately before administration raises the pH and reduces discomfort, but also shortens epinephrine stability because the catecholamine degrades more rapidly above 5.5. Production pharmacists and veterinary practitioners must therefore avoid preparing bicarbonate-buffered epinephrine-lidocaine admixtures for extended storage.

During manufacturing of these combined solutions, the epinephrine is added to the lidocaine base or salt after the antioxidant, typically sodium metabisulfite, has been dissolved and the bulk solution is sparged with nitrogen. Glass cartridge filling requires backfilling with nitrogen before sealing because the rubber plunger closure does not provide an absolute gas barrier over prolonged storage. A critical processing conflict is the susceptibility of epinephrine to oxidation by trace metal ions originating from rubber stopper extracts; closures are coated or washed to limit extractables. The finished product is tested for pH, lidocaine assay, epinephrine assay, and degradation products by high-performance liquid chromatography with UV detection; epinephrine degradation is commonly reported as the sum of adrenochrome and related catecholamine impurities. Compliance for veterinary use follows the relevant human pharmacopoeial monograph where veterinary monographs are absent; in the United States, compounding from approved products is governed by 21 CFR 530 and USP <797> for sterile preparation.

Maintenance of intraoperative mydriasis in cataract and corneal procedures requires epinephrine concentrations far below those used in emergency injection. A common working dilution is prepared by adding 0.5 mL of 1 mg/mL epinephrine injection to 500 mL of balanced salt solution, yielding an epinephrine concentration of 1 µg/mL (1:1,000,000). The diluted irrigating solution is used to keep the pupil dilated after mechanical dilation and to reduce bleeding from iris vessels during phacoemulsification and anterior chamber surgery in dogs, cats, and horses. Because the final dilution has a pH near physiological range, epinephrine stability is poor; the solution is prepared immediately before use and is discarded after the procedure rather than stored. Commercially available epinephrine injection products often contain sodium metabisulfite and acidifying agents; only formulations without antimicrobial preservatives and with documented low endotoxin content are used for intraocular protocols. The irrigating solution must be filtered through a 0.22 µm filter before use, and the surgical team must verify that no visible particulate matter is present after dilution.

In ophthalmic preparations, the primary process risk is destabilization of the catecholamine by ambient oxygen and light during the surgical field. Prolonged exposure under the operating microscope accelerates the conversion to adrenochrome, which is detected as a pink hue and is considered unsuitable for intraocular use. Published stability data for 1 µg/mL epinephrine in lactated Ringer’s or balanced salt solution are limited, and no harmonized veterinary monograph specifies a maximum in-use period; therefore the operational boundary is preparation within 4 h of surgery and protection from light. Some veterinary ophthalmologists use epinephrine at 1:10,000 as an intracameral injection in small volumes to control acute iris hemorrhage, but this is an intraoperative technique rather than a formulated end product. For the raw API supplier, the relevant specifications are low endotoxin content, absence of particulate contamination, and a certificate of analysis showing related substances below 0.5% by HPLC.

Topical Vasoconstriction is Concentration-Dependent and Must Not Be Substituted for Surgical Hemostasis

Dilution of the 1 mg/mL injection product with preservative-free sterile saline to 1:10,000 (100 µg/mL) produces a solution that can be applied to exposed capillary beds during oral, periodontal, or dermatologic procedures in veterinary patients. The solution is typically prepared by adding 1 mL of 1:1000 epinephrine injection to 9 mL of 0.9% w/v sodium chloride for immediate application. The mechanism is alpha-adrenergic vasoconstriction, which reduces small-vessel bleeding and improves surgical field visibility; it does not control arterial hemorrhage or replace ligation, electrocautery, or compression. Application is restricted to small surface areas because epinephrine can be absorbed systemically through mucosal membranes, producing transient tachycardia, hypertension, or arrhythmia. For feline patients, systemic absorption is a particular concern because of increased myocardial sensitivity to catecholamines; published veterinary toxicology data support limiting the total applied volume and avoiding repeated soaking of large sponges.

The soaked gauze or cottonoid is prepared at the point of use and is not autoclaved because heat degrades epinephrine and may generate adrenochrome. The solution must be protected from light during surgery; discolouration from clear to pink or brown is the visual release criterion for rejection. No official veterinary monograph specifies a beyond-use date for diluted topical epinephrine, but the low pH of the saline dilution is not sufficient to stabilize the catecholamine for more than a few hours at room temperature. As a result, compounding records under USP <795> should document preparation time, concentration, site of application, and lot number of the source injection. For raw API intended for topical solution manufacturing, particle size and pyrogen control are less critical than chemical purity, but the manufacturer must still provide a certificate of analysis conforming to the epinephrine monograph with related substances controlled.

When Direct Compression Meets Catechol Oxidation in Low-Dose Tablet and Capsule Compounding

Solid oral dosage forms containing epinephrine present a double constraint: the active substance is potent and oxidation-sensitive, while gastrointestinal and hepatic first-pass metabolism severely restricts systemic exposure after oral administration. In veterinary compounding practice, tablets and capsules are therefore not intended as first-line systemic therapy; they are prepared as low-dose triturations for local oral mucosal delivery, research protocols, or species-specific doses when no licensed injectable presentation can be safely divided. A standard geometric dilution is prepared using lactose monohydrate or microcrystalline cellulose as the diluent, with epinephrine hydrochloride first blended with an equal mass of diluent, then progressively doubled until the required final potency is reached. The target content for compounded solid dosage forms is typically 90.0–110.0% of label claim, tested by high-performance liquid chromatography with UV detection, and uniformity is assessed according to USP <905>.

Wet granulation with water is avoided in production because epinephrine is unstable in aqueous alkaline or neutral media and may degrade during drying. If granulation is required for tablet compression, a nonaqueous hydroalcoholic granulation with low water activity and antioxidant addition is used, followed by vacuum drying below 40°C. Capsule filling is performed manually or with semiautomatic equipment inside a controlled environment because the bulk powder is light-sensitive and hygroscopic. Finished capsules and tablets must be packaged in opaque containers with desiccant; a release specification for moisture content below 1.0% w/w is commonly applied to minimize hydrolysis of the catecholamine. There are no harmonized veterinary monographs for epinephrine tablets or capsules, and published data for this specific configuration are limited; any commercial development would require stability studies under ICH Q1A conditions to establish degradation profiles in primary packaging.

For tablet manufacturing, direct compression is preferred over roller compaction because the heat and pressure of dry granulation may induce localized amorphous zones that accelerate oxidation. A low-dose tablet formulation contains epinephrine hydrochloride triturated with anhydrous lactose or microcrystalline cellulose, crospovidone as disintegrant, and magnesium stearate as lubricant at 0.5% w/w. Tablets are compressed to a small-diameter compact and disintegration is tested under USP <701> in 0.1 N HCl. Capsule filling uses size 3 or 4 hard gelatin shells to accommodate small fill weights; the filled capsules are dedusted to remove surface powder that could cause cross-contamination. Because epinephrine is light-sensitive, the compression suite is equipped with yellow or low-UV lighting, and bulk hold times are limited to 8 h before final packaging into amber glass or foil-backed blister compartments.

In the veterinary pharmaceutical supply chain the term premix is reserved for homogeneous feed-incorporated or dilution-ready intermediates, and epinephrine has no recognized feed-premix application. Oral administration to food-producing species would expose the drug to extensive presystemic metabolism by catechol-O-methyltransferase and monoamine oxidase in the gastrointestinal tract and liver, resulting in negligible and unpredictable systemic concentrations. More critically, 21 CFR 530.41 prohibits extralabel use of drugs in or on animal feed, and no approved epinephrine feed additive exists in the United States. A raw API lot labelled as “premix grade” for epinephrine should be interpreted as a bulk powder or granulated intermediate intended for further pharmaceutical dilution, not as a feed ingredient; the certificate of analysis must be reviewed for particle morphology, residual solvents, and related substances before routing to a sterile or nonsterile manufacturing line.

For manufacturers that purchase the API as granules or powder for compounding, the granules may be a physical trituration of epinephrine hydrochloride with a diluent to improve handling safety and blend uniformity. Such granulated intermediates should be tested for blend uniformity using stratified sampling and HPLC assay before further dilution, because segregation of high-potency fines can occur during transfer. A production-scale bottleneck is the need for containment of a potent catecholamine powder; open handling is not permissible where airborne dust may contact operators or contaminate adjacent insulin or beta-lactam lines. Cleaning validation for manufacturing equipment after epinephrine use should include swab limits and visual inspection, with analytical methods derived from risk-based exposure calculations. No feed-premix, water-soluble powder, or oral solution for delivery in drinking water is supported by published residue or efficacy data in any major veterinary market.